New Two-Pronged attack tested for tough liver cancers
NCT ID NCT07268131
Summary
This study is testing a combination treatment for liver cancer that has grown too much for standard surgery. Patients will receive a targeted chemotherapy procedure (TACE) plus an immunotherapy drug (QL1706) before their tumor is removed, and then continue the immunotherapy afterward. The goal is to see if this approach can better control the cancer and improve outcomes for patients with more advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.